Saif Rehman, MD
Nephrology · Kissimmee, FLNPI 1386747798
Payments from drug & device makers
Across 53 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$216
- AstraZeneca$172
- Vifor Pharma, Inc.$161
- Baxter Healthcare$128
- Vantive US Healthcare LLC$116
- GSK$88
- plus $434 from 13 others
What the payments were for
- Food & beverage$1,315100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $216 |
| AstraZeneca | 9 | $172 |
| Vifor Pharma, Inc. | 7 | $161 |
| Baxter Healthcare | 5 | $128 |
| Vantive US Healthcare LLC | 4 | $116 |
| GSK | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Fresenius USA Marketing, Inc. | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 2 | $57 |
| Travere Therapeutics, Inc. | 2 | $55 |
| Nxstage Medical, Inc. | 1 | $45 |
| Bayer | 2 | $34 |
| Akebia Therapeutics Inc | 2 | $23 |
| Amgen | 1 | $20 |
| Novo Nordisk | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Cormedix Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$159
How this compares
$1,315 in reported general payments places this provider in the 40th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 26 | $76,664 |
| ProcritEpoetin Alfa | 26 | $33,276 |
| Sevelamer Carbonate | 25 | $5,884 |
| Cinacalcet Hcl | 11 | $3,888 |
| Calcitriol | 31 | $695 |
| Losartan Potassium | 20 | $501 |
| Metoprolol Tartrate | 21 | $248 |
| Furosemide | 23 | $138 |
| Torsemide | 14 | $129 |
| Amlodipine Besylate | 23 | $43 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Kissimmee
- Jorge LarranagaKissimmee$825K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.